

November 09, 2024

The Manager - Listing National Stock Exchange of India Limited, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India The Manager - Listing BSE Limited, Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001, Maharashtra, India

Dear Sir/Madam,

Subject	:	<u>Unaudited Financial Results of HealthCare Global Enterprises Limited ("the</u> <u>Company")</u>
Stock Code	:	<u>BSE – 539787, NSE – HCG</u>
Reference	:	<u>Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure</u> <u>Requirements) Regulations, 2015 ("SEBI LODR Regulations")</u>

Further to our intimation dated October 24, 2024, we wish to inform you that, the Board of Directors of the Company ("Board"), at their meeting held on this day, November 09, 2024, *inter alia*, has considered and approved the following agenda:

- 1. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and six months ended September 30, 2024, together with the Limited Review Report thereon.
- Signing of Business Transfer Agreement ("BTA"), with HCG NCHRI Oncology LLP, a wholly owned subsidiary, for the acquisition of the oncology business of HCG NCHRI Oncology LLP, located at Nagpur, on a slump sale basis. The Company shall make detailed disclosure under Regulation 30 of SEBI LODR Regulations in this regard, separately.
- 3. Signing of Business Transfer Agreement ("BTA"), with HCG NCHRI Oncology LLP, a wholly owned subsidiary, for the transfer of its diagnostic business under the brand name "Triesta" and the PET -CT and Cyclotron business located at Chennai, on a slump sale basis. The Company shall make detailed disclosure under Regulation 30 of SEBI LODR Regulations in this regard, separately.
- 4. Issue and allotment of 15,999 (Fifteen Thousand Nine Hundred Ninety Nine) equity shares of the Company of INR 10 each, upon exercise of Employee Stock Options in accordance with the existing Employee Stock Option Schemes of the Company.

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027. 080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489





5. Resignation of Mr Jeyandran Venugopal (DIN: 07085479), as an Independent Director of the Company with effect from the close of business hours of November 09, 2024. The Company shall make detailed disclosure under Regulation 30 of SEBI LODR Regulations in this regard, separately.

Pursuant to Regulation 33 read with Schedule III of the SEBI LODR Regulations, we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and six months ended September 30, 2024, together with the Limited Review Report thereon, as approved by the Board. The financial results are also being made available on the Company's website at www.hcgoncology.com.

The Meeting of the Board of Directors commenced at 10.45 a.m. and concluded at 6.00 p.m.

Kindly take the intimation on record and acknowledge receipt of the same.

Thanking you,

For HealthCare Global Enterprises Limited

Sunu Manuel Company Secretary & Compliance Officer

Encl: As above

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027. 080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



Chartered Accountants

Embassy Golf Links Business Park Pebble Beach, B Block, 3rd Floor No. 13/2, off Intermediate Ring Road Bengaluru - 560 071, India Telephone: +91 80 4682 3000 Fax: +91 80 4682 3999

Limited Review Report on unaudited standalone financial results of HealthCare Global Enterprises Limited for the quarter ended 30 September 2024 and year to date results for the period from 1 April 2024 to 30 September 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of HealthCare Global Enterprises Limited

- We have reviewed the accompanying Statement of unaudited standalone financial results of HealthCare Global Enterprises Limited (hereinafter referred to as "the Company") for the quarter ended 30 September 2024 and year to date results for the period from 1 April 2024 to 30 September 2024 ("the Statement").
- 2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BSR&Co.LLP

Chartered Accountants Firm's Registration No.:101248W/W-100022

Vikash Gupta Partner Membership No.: 064597 UDIN:24064597BKDHRL9495

Bangalore 09 November 2024

Registered Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063 Page 1 of 1

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

HealthCare Global Enterprises Limited CIN : L15200KA1998PLC023489 Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Kamataka, India Corp. Office: Tower Block. Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Kamataka, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED AND SIX MONTHS ENDED 30 SEPTEMBER 2024	

							s except share data
Sl. No.	Particulars	Quarter	Preceding quarter	Corresponding	Six months	Six months	Previous year
		ended	ended	quarter ended	ended	ended	ended
		30 September 2024 Unaudited	30 June 2024	30 September 2023	30 September 2024	30 September 2023	31 March 2024
1	Income	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	(a) Revenue from operations	30,596	29.294	28,200	59,890	55,352	109,929
	(b) Income from government grant	71	67	75	138	146	328
	(c) Other income (refer note 4)	1,024	1.050	213	2,074	396	
	Total income						1,360
	Total income	31,691	30,411	28,488	62,102	55,894	111,617
2	Expenses					1	
	(a) Purchases of medical and non-medical items	7,346	6,761	6,255	14,107	13,038	24,508
	(b) Changes in inventories	(161)	(70)	117	(231)	(120)	63
	(c) Employee benefits expense	5.374	5,415	4.942	10.789	9,820	19,715
	(d) Finance costs	2.016	1,934	1,098	3,950	2,067	4,797
	(e) Depreciation and amortisation expense	2,713	2,584	2,328	5,297	4,492	9,420
	(f) Medical consultancy charges	5,950	5,691	5,427	11.641	10,579	21,292
	(g) Other expenses (refer note 4)	6,354	6,575	6,493	12,929	12,386	24,726
	Total expenses	29,592	28,890	26,660	58,482	52,262	104,521
3	Profit before exceptional items and tax (1-2)	2,099	1,521	1,828	3,620	3,632	7,096
	Exceptional items, net (loss) (refer note 2)	-	-	-			(1,610
	Profit before tax (3+4)	2,099	1,521	1,828	3,620	3,632	5,486
	Tax expense	2,077	1,000	1,020	5,020	5,052	-1,400
- Č	- Current tax	928	588	623	1,516	1,166	2.519
1	- Deferred tax	(432)	(239)	(165)	(671)	(273)	
- 1	Total tax expense	496	349	458	845	893	2,090
7	Profit for the period / year (5-6)	1,603	1,172	1,370	2,775	2,739	3,396
	Other comprehensive income / (loss)	1,003	1,1/2	1,370	2,775	2,739	3,390
	Items that will not be reclassified subsequently to profit or loss						
	- Remeasurements of the defined benefit plans						(39
1	- Remeasurements of the denned bencht plans - Income tax effect on above		-	-	-		10
			-	-	-	-	
1	Other comprehensive (loss) for the period / year, net of tax	-	-	-	-	-	(29
9	Total comprehensive income for the period / year (7+8)	1,603	1,172	1,370	2,775	2,739	3,367
10	Paid-up equity share capital (Face value of Rs 10 each)	13,939	13,935	13,926	13,939	13,926	13,929
	Reserves, i.e., 'Other equity'						104,930
	Earnings per equity share (face value of Rs. 10 each)	Not annualised	Not annualised	Not annualised	Not annualised	Not annualised	Annualised
	(a) Basic (Rs.)	1.15	0.84	0.98	1.99	1.96	2.44
	(b) Diluted (Rs)	1.14	0.83	0.98	1.97	96	2.42
	See accompanying notes to the Standalone Financial Results						



IABLA CONTROLATION TO AND THE CALL NOT THE CONTROL NOT THE CALL NOT THE CALL NOT THE CONTROL NOT THE CALL NOT THE CAL					
Read Office Standards Suppose Read					
SATEMENT OF UNAURITE STATULATER LINE ROW TO QUARTEL SADE AND STATUMER 2024 Status Colspan="2">Status Colspan="2" Status Colspan="2" Of Colspan="2" Of Colspan="2" Of Colspan="2" Status Colspan="2" Of Colspan="2" Of Colspan="2" Of Colspan="2" Of Colspan="2" Of Colspan="2" Of Colspan="2" <		Regd. Office: HCG Tower, No. 8, P k	Kalinga Rao Road, Sampar	igi Rama Nagar, Bengah	iru 560 027, Karnataka, India
STADALONE BALANCE SHIFT Base A set A set Image: Construct state JA set (1) JA set (2) JA set (2) Image: Construct state JA set (2) JA set (2) JA set (2) Image: Construct state JA set (2) JA set (2) JA set (2) Image: Construct state JA set (2) JA set (2) JA set (2) Image: Construct state JA set (2) JA set (2) JA set (2) Image: Construct state JA set (2) JA set (2) JA set (2) Image: Construct state JA set (2) JA set (2) JA set (2) Image: Construct state JA set (2) JA set (2) JA set (2) Image: Construct state JA set (2) JA set (2) JA set (2) Image: Construct state JA set (2) JA set (2) JA set (2) Image: Construct state JA set (2) JA set (2) JA set (2) Image: Construct state JA set (2) JA set (2) JA set (2) Image: Construct state JA set (2) JA set (2) JA set (2) Image: Construct state (2)					
V Art B Art		STATEMENT OF UNAUDITED STANDALONE FINANCI	AL RESULTS FOR TH	E QUARTER ENDED	AND SIX MONTHS ENDED 30 SEPTEMBER 2024
Jump Jump Jump 1 Nature 2014 Aukleon 1 Nature 2014 Aukleon 10 Peoply and Augement 1.37 5.15 10 Cipali vect is project 1.37 2.18 11 Cipali vect is project 1.31 2.24 12 Cipali vect is project 2.30 2.274 13 Cipali vect is project 3.35 4.152 14 Cipali vect is project 2.30 2.210 15 Cipali vect is project 3.35 4.152 16 Obstransition 2.30 2.310 16 Cipali vect is project is		STANDALONE BALANCE SHEET		(Rs in Lakhs)	
A MSRTS Landeduct 1 Marked Autified 1 Marked 59/02 51,13v 0) Cogst with a program. 39/02 51,13v 0) Cogst with a program. 33,07 12,04 (d) Good and 13,07 12,04 (d) Good and 13,07 12,04 (d) Door framely and the set of the		Destinutore			
A NetSTS SetSTS I Numerican starts 9.072 5.1 by IO Optimit vok as program 3.3 37 5.6 p IO Optimit vok as program 3.3 37 5.6 p IO Optimit vok as program 3.3 37 5.6 p IO Optimit vok as program 3.3 37 5.6 p IO Optimit vok as program 3.0 a 5.7 p IO Optimit vok as program 3.0 a 5.1 p IO Optimit vok as program 8.0 a 5.1 p IO Optimit vok as program 8.0 a 5.1 p IO Optimit vok as program 8.0 a 5.1 p IO Optimit vok as program 8.0 a 5.2 p IO Optimit vok as program 8.0 a 5.2 p IO Optimit vok as program 8.0 a 5.2 p IO Optimit vok as program 8.0 a 5.2 p IO Optimit vok as program 5.2 p 5.2 p IO Optimit vok as program 5.2		rarticulars			
III Import. pint and argument 9.072 9.13y III Control with imports 3.347 3.549 III Control with imports 3.347 2.103 III Control with imports 2.04 2.74 III Control with imports 2.04 2.74 III Control With imports 2.04 2.74 III Control With imports 2.04 3.74 III Control With imports 2.06 3.021 III Control With imports 2.06 3.021 III Control With imports 2.06 3.021 III Control With imports 2.02 3.021 III Control With imports 2.02 2.012 III Control With imports 2.02 2.012 III Control With imports 2.02 2.012 III Control With imports 2.023 2.012 III Control With import imports 2.013 2.012 III Control With imports 2.013 2.014 III Control With imports 2.015 2.016 III Control With imports 2.012 2.014					
9 1.0 Cipilit work in program 3.37 3.69 10 Regular constrangular and the state of the stat	I		50.077	51.130	
1 Register/area asim 3.007 3.2.102 10) Ober intragible asim 2.045 2.734 10) Debre intragible asim 2.045 2.744 10) Incomings tofe rows and 0 3.136 2.045 10) Debre intragible asims 3.007 3.04 10) Debre intragible asims 3.007 3.04 10) Debre intragible asims 3.002 1.02 10) Debre intragible asims 3.002 1.02 10) Ober intragible asims 3.002 1.02 10) Ober intragible asims 3.002 1.02 10) Ober intragible asims 3.02 2.002 10) Ober intragible asims 3.02 2.002 10) Ober intragible asims 3.02 2.003 10) Ober intragible asims 3.02 2.003 10) Ober intragible asims 3.02 2.004 10) Ober intragible asims 3.02 2.004					
Image: state in the state in					
Image: Problem Starter					
0 00 Investment notine or 2 and 5 1) 51,115 50,022 0 0 Other framerial ance 9,000 8,475 0 0.0 Detrat assets (not) 3,314 5,422 0 0.0 Detrat assets (not) 3,314 5,422 0 0.0 Detrat assets (not) 3,314 5,422 0 0.0 Detrat assets (not) 3,314 5,423 0 0.0 Detrat assets (not) 3,314 5,423 0 0.0 Detrat assets (not) 2,332 2,102 0 0.0 Detrat assets (not) 2,233 2,102 10 0.0 Detrat cassets 2,232 2,423 10 1.0 Tote inscribation 2,233 2,2437 10 1.0 Detrat cass and cass equivalunt above 3,342 2,2437 10 1.0 Detrat cass and cass equivalunt above 3,342 2,2437 10 1.0 Detrat cass and cass equivalunt above 3,342 2,4037 10 1.0 Detrat cass and cass equivalunt above 3,342 2,4037 10 1.0 Detrat cass and cass equivalunt abov					
Image: start of the start of		(f) Financial assets			
0.0 Ober funcial asets9.0009.07(0) Ober funcial asets3.3345.4250. Ober convent asets3.3425.4250. Ober convent asets3.3425.4250. Ober convent asets18.848167.8850. Ober convent asets2.5222.1020. Or funcial asets2.5103.0410. Tatal searcher2.5103.0410. Tatal converted asets2.5103.04110. Class asets2.5103.04110. Class ads chequisation beine3.021.47110. Class ads chequisation beine3.021.47110. Class ads chequisation beine3.042.54010. Ober runna and cata equisation beine3.042.54010. Ober runna asets3.0422.640Tatal asets3.045.13711. Italian curvet asets3.045.13712. Ital curvet asets3.045.13713. Ital curvet asets3.045.13714. Ital curvet asets3.1391.149.9015. Ober curvet asets3.1391.149.9016. Derono sinter capital13.0391.149.9017. Ital curvet asits3.1502.59810. Net curvet asits3.1502.59810. Derono sinter capital3.1502.59810. Derono sinter capital3.1602.59810. Derono sinter capital est curvet asits3.1602.49810. Derono sinter convertications3.1401.12810. Derono sinter convertications3.1502.598 <td></td> <td>(i) Investments (refer note 3 and 5)</td> <td>51,315</td> <td>50,632</td> <td></td>		(i) Investments (refer note 3 and 5)	51,315	50,632	
Image: starting the starting					
03.3.45.4.200.00 converta assets3.0021Carcen sets10.2.2.201 factorization2.3.2.201 factorization2.3.2.201 factorization2.3.2.201 factorization2.3.2.201 factorization2.3.2.2101 factorization2.3.2.2101 factorization2.3.2.2101 factorization2.3.2.2101 factorization2.3.2.2101 factorization2.3.2.2101 factorization2.3.2.2111 factorization2.3.4.2122 factorization3.3.4.4132 factorization2.4.4142 factorization2.4.4151 factorization2.4.4162 factorization2.4.4171 factorization2.4.4182 factorization13.9.99191 factorization13.9.99101 factorization14.9.99101 factorization14.9.99101 factorization3.1.99101 factorization3.1.99101 factorization3.1.99111 factorization3.1.99121 factorization3.1.99131 factorization3.1.99141 factorization3.1.99151 factorization3.1.99161 factorization3.1.99171 factorization <td></td> <td></td> <td></td> <td></td> <td></td>					
00.0 Oder non-surver assets3.0%21.1%2Totat non-crient assets0.83.64.400.61.64.846) I fexerioliza sets2.2.532.2.1026) I fexerioliza assis2.5.1020.0.1710) Cash and cash equivalents above2.2.532.2.2.6010) Cash and cash equivalents above3.31.1310) Ohdr survert assis3.0422.5.6910) Ohdr survert assis3.7.928.1.8011Eaguis functional assis3.7.921.8.7.9912Tatal asses3.7.922.16.79913Tatal asses2.40.772.16.79914Eaguis func expendal1.0.3041.0.9016Eaguis func expendal1.0.3041.0.9010) Ohdr curvert fubilities1.12.144118.85911Labilities1.1.911.1.8910) Ohdr curvert fubilities2.8.322.6.0311Labilities1.1.911.1.1810) Ohdr curvert fubilities3.8.322.6.0311) Cash abilities1.1.911.1.1812) Ohdr curvert fubilities3.8.322.6.0313) Ohdr curvert fubilities3.5.352.3.9914) Ohdr curvert fubilities3.5.362.3.9915) Ohder on curvert fubilities3.5.362.3.9916) Ohder on curvert fubilities3.5.362.3.9916) Ohder on curvert fubilities3.5.362.3.9916) Ohder on curvert fubilities3.5.362.3.9916) Ohder on curvert fubilities3.5.362.3.99 <td></td> <td></td> <td></td> <td></td> <td></td>					
Total and current asols 183,640 187,640 11 Current asols 2.332 2.102 (0) France asols 25.130 30,417 (10) Carl card asols 25.130 30,417 (10) Carl card card card card card card card card					
IICurrent satest					
Image: space of the second s	п		183,043	10/,482	
Image: Construction of Transmit and a set of the s			2.332	2.102	
Image: space of the second s				2.172	
Image:			25,130	20,417	
(v) Loans(v) Loans(v) Loans(v) Ober current assets3.9022.639Total current assets3.9022.639Total current assets2.03792.18,789BEQUITY AND LLABILITIES		(ii) Cash and cash equivalents	22,323		
(a) Other inaurent assets2.0142.253(b) Other current assets97.23651.207Total accreat assets20.037218.7897 total assets20.037218.7897 total assets20.037218.7898 EQUITY AND LIABILITIES13.93913.929(b) Other country induce captal10.9205104.9907 total asset122.144118.85911 Labilities10.9205104.9907 Monecurrent labilities28.227552.001(a) Other inaucal labilities28.227552.001(a) Other inaucal labilities9817.113(a) Other inaucal labilities (net)3.1592.5997 Monecurrent labilities (net)3.1592.5997 Other inaucal labilities3.1592.5997 Indicast labilities (net)3.1592.5997 Other inaucal labilities3.1592.5997 Total occurrent labilities3.1692.5997 Total occurrent labilities3.1692.5997 Total occurrent labilities3.1692.5997 Total occurrent labilities3.1692.387(a) Other inaucal labilities3.1692.387(b) Other inaucal labilities3.1692.184(c) Total occurrent labilities3.1692.184(d) Care labilities3.1692.184(d) Other inaucal labilities3.1692.184(d) Other inaucal labilities3.1692.184(d) Other inaucal labilities3.1692.184(d) Other i		(iii) Bank balance other than cash and cash equivalents above	502	1,473	
i 0 Other current assets3.9922.699Total assets240.9792118,789Total assets240.9792118,789B EQUITY AND LIABILITIES11(a) Equity share capital13.93913.929(b) Other cquity10x.203104.930Total asset122.144118.859Total asset capital10.203104.930(a) Equity share capital122.144118.859Total capity122.144118.859(b) Other cquity28.90220.053(c) Browsings28.20220.053(c) Browsings28.20220.053(d) Dother famical liabilities3.1592.599(d) Other famical liabilities3.1592.599(d) Other famical liabilities3.1592.599(d) Other famical liabilities3.1592.599(d) Other famical liabilities3.0882.387(d) Other famical liabilities3.0882.387(d) Other famical liabilities3.0882.387(d) Forwings3.0882.387(d) Forwings3.0882.387(d) Total castanding dues of micro enterprises and small enterprises424Total castanding dues of micro enterprises and small enterprises424(d) Other famical liabilities2.2642.013(d) Other famical liabilities2.2642.013(d) Other famical liabilities2.2642.013(d) Other famical liabilities2.2642.013(d) Carrent liabilities2.2642.0					
Total sates 97.336 \$1,07 Total sates 240.979 216,780 B EQUITY AND LIABILITIES 13.939 13.929 (a) Equity share capital (13.939 (13.929 (b) Other capity 108.205 (14.930) Total capity 122.144 (18.859 II Liabilities 28.292 26.053 (a) Fornew ags 28.292 26.053 (b) Other functial liabilities 42.75% 32.041 (a) Other functial liabilities 98 172 (b) Other functial liabilities 98 173 (c) Defreed tax liabilities (net) 3.159 2.599 Total outstanding dues of metro entreprises and small entorprises 3.308 2.387 (a) Other functial liabilities 3.085 2.387 (a) Fornew agits 19.033 13.496 (b) Other owaids liabilities 3.085 2.387 (c) Fornew agits 13.270 12.283 (f) Other functial liabilities 3.446 4.513 (b) Other carrent liabilities 2.264 2.013 (c) Forne size is liabilities 2.246 2.013 (f) Total south dues of metro enterprises and small enterprises 4.34 4.14 Total outstanding dues			1		
Total assets240.979218,789BEQUITY AND LIABILITIES-IEquity13.92913.929(b) Other equity108,205104.930Total equity122,144118,859IILiabilities-1Non-current liabilities-(a) Funcals liabilities-(b) Porvision28,29226,055(c) Dervo migs28,29226,055(d) Horson migs-5300(d) Other numcul liabilities-5300(d) Other numcul liabilities-5300(d) Other numcul liabilities-5300(d) Other numcul liabilities3,1502,590Total acai liabilities-5300(d) Other numcul liabilities3,0452,837(ii) Locat liabilities3,0452,837(d) Fornow migs19,93313,496(i) Dacrisol liabilities3,0452,837(d) Fornow migs13,27012,223(iii) Other dust liabilities3,3463,346(i) Dortificia3,3463,446(i) Other current liabilities2,2642,013(i) Other current liabilities					
BEQUITY AND LIABILITIESIEquity13.93910 Equity since apital108.205(10) Gotter equity108.205Total equity122,14411Monetarent liabilities(1)Labilities(1)Labilities(1)Encode liabilities(1)Encode liabilities(1)Encode liabilities(1)Encode liabilities(1)Encode liabilities(1)Encode liabilities(1)Encode liabilities(1)Encode liabilities(1)Encode liabilities(1)Encode liabilities (nc1)(2)Derend liabilities (nc1)(3)Encode liabilities (nc1)(4)Encode liabilities (nc1)(4)Encode liabilities(5)Encode liabilities(6)Force liabilities(7)Encode liabilities(1)Encode liabilities(1)Encode liabilities(1)Encode liabilities(2)Encode liabilities(3)Encode liabilities(4)Encode liabilities(1)Encode liabilities(1)Encode liabilities(1)Encode liabilities(1)Encode liabilities(2)Encode liabilities(3)Encode liabilities(4)Encode liabilities(5)Encode liabilities(6)Encode liabilities(6)Encode liabilities(6)Encode liabilities <td></td> <td></td> <td></td> <td></td> <td></td>					
IEquivyI10 Equity share capital13.93013.93010 Other equity108.205104.93010 Other equity102.144118.85911Labilities112Labilities113Non-current liabilities214Other equity10.820215Portowings28.20216Derrowings28.20217Other francial liabilities91811.1131.11319Provisions1.10110Derrowings3.15010Derrowings3.15011Derrowings3.15012Current liabilities (net)3.15013Cata non-current liabilities3.15014Total one-current liabilities3.03315Total one-current liabilities3.03316ID current liabilities3.03517Total outstanding dues of metro enterprises and small enterprises3.140610Derrowings13.27017Total outstanding dues of metro enterprises and small3.274110Other francial liabilities3.44610Other francial liabilities3.44610Other francial liabilities3.44610Other francial liabilities3.44610Total outstanding dues of redioers other than nietor enterprises and small3.274310Current liabilities (net)3.44610Other current liabilities3.446		1 otal assets	240,979	218,/89	
IEquityI10 Equity share capital13 93013 93010 Debre equity108 205104 93010 Debre equity122,144118,85911Labilities112Labilities113Non-current liabilities21410 Borrowings28,20216) Dorrowings28,20226,05316) Dorrowings28,20226,05316) Dorrowings28,20226,05316) Dorrowings1,1011,11317Order financial liabilities981821,1441,113191,1131,113191,1132,50910Total one - current liabilities3,15010Dorrowings19,03311Total one - current liabilities3,15010) Borrowings19,03313,40610) Dorrowings10,03313,40610) Dorrowings10,03313,40610) Dorrowings10,03313,40610) Dorrowings10,03313,40610) Dorrowings13,27012,82310) Dorrowings13,27012,82310) Dorrowings13,27012,82310) Orrowings12,2442,01310) Dorrowings2,2642,01310) Dorrowings2,2642,01310) Debre runent liabilities3,4464,51310) Orrowings12,2442,01310) Orrowings12,2642,01310) Orrent ax liabilities (ner) <t< td=""><td>в</td><td>EQUITY AND LIABILITIES</td><td></td><td></td><td></td></t<>	в	EQUITY AND LIABILITIES			
(b) Equip share capalal(13) 599(13) 599(b) Other capity108,209(104,930Total capity122,114118,8591Liabifities11Non-current liabilities11Non-current liabilities28,202(i) Eranscias liabilities28,202(ii) Consonings28,202(ii) Casea liabilities242,759(ii) Casea liabilities (net)28,202(ii) Consonings11/91(ii) Consonings11/91(ii) Consonings31,50(ii) Consonings31,50(ii) Other financial liabilities (net)-(iii) Other financial liabilities31,50(ii) Other financial liabilities31,50(ii) Other financial liabilities30,8510 de financeal liabilities30,8510 de financeal liabilities30,85(iii) Toda payables-(iii) Toda payables-(iii) Toda payables-(iv) Other financial liabilities3,440(iv) Other financial liabilities2,264(iv) Other financial liabilities3,440(iv) Other financial liabilities3,440(iv) Other financial liabilities3,440(iv) Other financial liabilities2,264(iv) Other financ		-			
Total equity122,144118,859IILiabilities-(a) Franciski labilities-(b) Bortow mags28,292(c) Franciski labilities-(i) Lasac labilities-(ii) Lasac labilities funct)98(ii) Deformed Liabilities funct)-(b) Provisions1.191(c) Defored tax liabilities funct)-(d) Other non-current liabilities3.150(d) Other non-current liabilities-(d) Other solution links-(e) Deforwings19,033(f) Franciski labilities-(h) Franciski labilities-(ii) Trade payables-(iii) Trade payables-(iii) Trade payables-(iv) Other francial labilities-(iv) Other francial labilities-(v) Other francial labilities-(d) Current Liabilities-(e) Provisions-(f) Other francial labilities-(h) Other francial labilities-(h) Other francial labilities-(h) Other francial labilities-(h) Other rent			13,939	13,929	
ItLiabilities1Non-current liabilities(a) Financials liabilities28.292(b) Foroxings28.2922.6.053(ii) Other financial liabilities28.2922.6.074(iii) Other financial liabilities981.1011.113(c) Defered tax liabilities (net)-(d) Other non-current liabilities (net)3.1502.7.748762.5877 total non - current liabilities75.4876) Deroxings19.033(ii) Case liabilities3.085(iii) Trade payables-Total outstanding dues of infero enterprises and small3.13.406(iii) Trade payables-(iv) Other financial liabilities3.446(b) Other current liabilities3.446(d) Other ranceurliabilities-(d) Other ranceurlities-(iii) Trade payables-(iii) Trade payables-(b) Other ranceurlities-(c) Provisions-(d) Current tabilities-(d) Current tabilities-(e) Provisions-(f) Other financial liabilities-(f) Other financial liabilities-(f) Other financial liabilities-(h)		(b) Other equity	108,205	104,930	
1Non-current liabilitiesImage: section of the s		Total equity	122,144	118,859	
1Non-current liabilitiesImage: section of the s					
(a) Financials liabilitiesu(i) Borrow mgs28.302(i) Lasse liabilities42.750(ii) Other financial liabilities42.750(iii) Other financial liabilities98(b) Provisions1.191(c) Deferent tax liabilities (net)-(d) Other non-current liabilities75.487Current liabilities75.487(a) Financials liabilities19.033(iii) Trade payables19.033(iii) Trade payables13.270(iii) Other runcent liabilities3.446(iii) Trade payables13.270(iii) Other runcent liabilities3.446(iii) Trade payables13.270(iii) Other runcent liabilities13.270(iii) Trade payables13.446(iii) Trade payables13.270(iii) Trade payables2.264(i) Other runcent liabilities3.446(iii) Trade payables13.270(iii) Trade payables2.264(iii) Trade payables3.446(iii) Trade payables3.446(iii) Trade payables3.446(iii) Other francial liabilities3.446(iii) Other francial liabilities2.264(iii) Other francial liabilities2.264(i) Other francial liabilities2.264(i) Other francial liabilities2.264(ii) Other francial liabilities2.264(iii) Trade aurrent liabilities2.264(iii) Trade aurrent liabilities2.264(iii) Trade aurrent liabilities2.3743(iii) Trade					
(i) Borrowings 28.292 26.053 (ii) Lease liabilities 42.756 32.061 (iii) Other financial liabilities 98 172 (b) Provisions 1.191 1.113 (c) Deferred tas liabilities (net) - 589 (d) Other non-current liabilities 75,487 62,887 7 dat non - current liabilities 75,487 62,887 (a) Financial liabilities 19.033 13,496 (ii) Dorrowings 19.033 13,496 (iii) Lease liabilities 3.085 2.387 (iii) Trade payables - - (iv) Other financial liabilities 3.446 4.513 (iv) Other financial liabilities 3.446 4.513 (iv) Other financial liabilities 2.264 2.013 (iv) Other financial liabilities 2.264 2.013 (iv) Other financial liabilities 1.562 1.477 (d) Other financial liabilities (net) 2.264 2.013 (e) Provisions 1.562 1.477 (d) Current tai liabilities (net) 2.64 2.013 (e) Provisions 1.562 1	I				
(ii) Lease liabilities42.75632.061(iii) Other manetial liabilities (net)98172(b) Provisions1.1911.113(c) Deferred tax liabilities (net)-589(d) Other non-current liabilities3.1502.599(d) Other non-current liabilities75,48762.587(a) Financials liabilities19.03313.496(ii) Borrowings19.03313.496(iii) Crase liabilities3.0882.387(iii) Trade payablesTotal outstanding dues of incro enterprises and small enterprises424414Total outstanding dues of ereditors other than micro enterprises and small13.27012.823(iv) Other current liabilities3.4464.513(b) Other current liabilities2.2642.013(c) Provisions1.5621.477(d) Current tax liabilities (net)2.642.201(d) Current tax liabilities (net)2.642.013(e) Provisions1.5621.477(d) Current tax liabilities (net)2.642.013Total equity and liabilities (net)2.63972.6378Total equity and liabilities (net)2.63972.6378Total equity and liabilities (28 702	26.053	
(iii) Other financial liabilities98172(b) Provisions1.1911.113(c) Deferred tax liabilities (net)-589(d) Other non-current liabilities3.1502.599Total non - current liabilities75,48762,587(a) Financials liabilities19,03313,496(i) Borrowings19,03313,496(ii) I case, liabilities3.0852.387(iii) Trade payablesTotal outstanding dues of intero enterprises and small13,27012,823(iv) Other function liabilities3,4464,513(b) Other current liabilities2.2642.013(c) Provisions1.5621.477(d) Current tas liabilities (net)2.642.201Total outstanding ties (net)2.642.201Total current liabilities43,34837,343Total equity and liabilities430,979218,789		-	1		
(b) Provisions1.1911.113(c) Deferred tax, liabilities (net)-589(d) Other non-current liabilities3.1502.599Total non - current liabilities75,48762,5872Current liabilities19.03313,496(i) Borrowings19.03313,496(ii) Lease liabilities3.0852.387(iii) Trade payables(iii) Trade payables(iv) Other innecial liabilities3.146-(iv) Other innecial liabilities3.0852.387(iv) Other financial liabilities3.27012,823(iv) Other innecial liabilities3.4464.513(b) Other current liabilities2.2642.013(c) Provisions1.5621.477(d) Current tax liabilities (net)264220Total current liabilities43.34837,343Total equity and liabilities240,979218,789			1		
(d) Other non-current liabilities3.1502.599Total non - current liabilities75,48762,5872Current liabilities19.03313.496(a) Franceals liabilities19.03313.496(ii) Borrowings19.03313.496(iii) Trade payables10.101 outstanding dues of micro enterprises and small enterprises424414Total outstanding dues of creditors other than micro enterprises and small13.27012.823(iv) Other current liabilities2.6642.013(b) Other current liabilities2.6642.013(c) Provisions11.5621.477(d) Current tax liabilities (net)2.642.013Total equity and liabilities43.34837.343Total equity and liabilities240.979218.789					
Total non - current liabilities75,48762,5872Current liabilities19,03313,496(i) Borrowings19,03313,496(ii) Lase liabilities3,0852,387(iii) Trade payables424414Total outstanding dues of micro enterprises and small enterprises424414Total outstanding dues of ereditors other than micro enterprises and small13,27012,823(iv) Other financial liabilities3,4464,513(b) Other current liabilities2,2642,013(c) Provisions1,5621,477(d) Current tax liabilities (net)264220Total equity and liabilities43,34837,343Total equity and liabilities240,979218,789				589	
2Current liabilities					
(a) Financials liabilities9(i) Borrowings19.03313.496(ii) Lease liabilities3.0852.387(iii) Trade payables11Total outstanding dues of micro enterprises and small enterprises424414Total outstanding dues of creditors other than micro enterprises and small13.27012.823enterprises3.4464.513(iv) Other functal liabilities2.2642.013(b) Other current liabilities1.5621.477(c) Provisions1.5621.477(d) Current tax liabilities (net)26420.13Total eutrent liabilities43.34837.343Total equity and liabilities240.979218.789		Total non - current liabilities	75,487	62,587	
(a) Financials liabilities9(i) Borrowings19.03313.496(ii) Lease liabilities3.0852.387(iii) Trade payables11Total outstanding dues of micro enterprises and small enterprises424414Total outstanding dues of creditors other than micro enterprises and small13.27012.823enterprises3.4464.513(iv) Other functal liabilities2.2642.013(b) Other current liabilities1.5621.477(c) Provisions1.5621.477(d) Current tax liabilities (net)26420.13Total eutrent liabilities43.34837.343Total equity and liabilities240.979218.789					
(i) Borrowings19.03313.406(ii) Lease liabilities3.0852.387(iii) Trade payablesTotal outstanding dues of enciror enterprises and small enterprises424414Total outstanding dues of encirors other than micro enterprises and small enterprises13.27012.823enterprises(iv) Other financial liabilities3.4464.513(b) Other current liabilities2.2642.013(c) Provisions1.5621.477(d) Current tax liabilities (net)264220Total current liabilities43.34837.343Total equity and liabilities240.979218.789	Z				
(ii) Lease liabilities3.0852.387(iii) Trade payablesTotal outstanding dues of micro enterprises and small enterprises424414Total outstanding dues of creditors other than micro enterprises and small13.27012.823(iv) Other financial liabilities3.4464.513(b) Other current liabilities2.2642.013(c) Provisions1.5621.477(d) Current tax liabilities (ner)264220Total equity and liabilities240,979218,789			19.022	13.404	
(iii) Trade payables424Total outstanding dues of micro enterprises and small enterprises424Total outstanding dues of ereditors other than micro enterprises and small13.270(iv) Other financial liabilities3.446(b) Other current liabilities2.204(c) Provisions1.562(d) Current tax liabilities (ner)26422042.202Total current liabilities43.34837.34337.343Total equity and liabilities240.979218.789218.789					
Total outstanding dues of iniero enterprises and small enterprises424414Total outstanding dues of creditors other than niero enterprises and small13.27012.823enterprises3.4464.513(iv) Other financial liabilities3.4464.513(b) Other current liabilities2.2642.013(c) Provisions1.5621.477(d) Current tax liabilities (net)264220Total eurrent liabilities43.34837.343Total equity and liabilities240.979218.789				2,007	
Total outstanding dues of creditors other than micro enterprises and small enterprises13.27012.823(iv) Other financial liabilities3.4464.513(b) Other current liabilities2.2642.013(c) Provisions1.5621.477(d) Current tax liabilities (net)264220Total current liabilities43,34837,343Total equity and liabilities240,979218,789			424	414	
(iv) Other financial liabilities 3,446 4,513 (b) Other current liabilities 2,204 2,013 (c) Provisions 1,562 1,477 (d) Current takibilities (ner) 264 220 Total current liabilities 43,548 37,343 Total equity and liabilities 240,979 218,789		Total outstanding dues of creditors other than micro enterprises and small	13,270	12.823	
(b) Other current liabilities 2.264 2.013 (c) Provisions 1.562 1.477 (d) Current tax liabilities (net) 264 220 Total equity and liabilities 43,348 37,343					
(c) Provisions 1.562 1.477 (d) Current tax liabilities (net) 264 220 Total current liabilities 43,348 37,343 Total equity and liabilities 240,979 218,789					
(d) Current tax liabilities (net) 264 220 Total current liabilities 43,348 37,343 Total equity and liabilities 240,979 218,789			1		
Total current liabilities43,34837,343Total equity and liabilities240,979218,789			1		
Total equity and liabilities 240,979 218,789					
See accompanying notes to the Standalone Financial Results		See accompanying notes to the Standalone Financial Results			



		lealthCare Global Ente	rprises Limited	
		CIN: L15200KA1998	3PLC023489	
	Regd. Office: HCG Tower, No. 8, P K			ru 560 027, Kamataka, India
	Corp. Office: Tower Block, Unity B			
1	STATEMENT OF UNAUDITED STANDALONE FINANCIA			
1	STATEMENT OF STATED STATEMENTED	LE RESCETOT ON TH	E QUINTER EREED	AND SIX MONTHS ENDED TO BET TEMPER SOL
	Standalone Cash Flow Statement		(Rs in Lakhs)	
<u> </u>	Standarone easily from Statement	For the six month	For the six month	
1	Particulars	ended	ended	
		30 September 2024	30 September 2023	
<u></u>		Unaudited	Unaudited	
	Cash flows from operating activities	2 (20)	2 (22	
ļ	Profit before tax	3,620	3,632	
	Adjustments for:			
	Finance costs	3,950	2,067	
	Gain on investment revalued at FVTPL	(16)	(6)	
1	Net gain on termination of lease	-	(2)	
1	Guarantee commission income	(88)	(119)	
	Remeasurement of contingent consideration (refer note 4)	(278)	-	
1	Finance lease income	(291)	(13)	
	Loss allowance on trade receivables	892	1.075	
	Expenses on employee stock option scheme	355	339	
	Interest income	(975)	(186)	
	Income from government grant	(138)	(146)	
J	Depreciation and amortisation expense	5,297	4,492	
	Net foreign exchange (gain)	(34)	(34)	
	Movements in working capital:			
	Changes in trade receivables	(5,572)	(4.271)	
	Changes in inventories	(231)	(4.271) (120)	
	Changes in loans, financial assets and other assets	(3,754)	(2,514)	
	Changes in roads, mathem assess and only assess	631	1,436	
1	Changes in provisions	163	251	
1	changes in provisions	105	251	
í	Cash generated from operations	3,531	5,881	
	Income taxes paid (net of refunds)	545	(2,425)	
í	Net cash generated from operating activities (A)	4,076	3,456	
1		1,010	5,110	
	Cash flows from investing activities			
	Fixed deposits invested	(250)	(1.041)	
1	Proceeds from maturity of fixed deposits	1,003	1,019	
	Acquisition of property, plant and equipment and others	(8,265)	(6,001)	
	Interest received	630	222	
	Investment in subsidiaries	(667)	(2,750)	
	Deferred Consideration for Investment in subsidaries	(210)	-	
	Proceeds from repayments of related party loans '	200	-	
	Proceeds from sub-lease receivable	318	-	
	Proceeds from disposal of property, plant and equipment	30	-	
	Net cash (used) in investing activities (B)	(7,202)	(8,551)	
	Carb Rome Come Complete and Million			
	Cash flows from financing activities	125	151	
	Proceeds from issue of equity shares			
	Proceeds from long-term borrowings	5,504	5.889 (500)	
	Repayment of long-term borrowings	(1.185) (1.022)	(500) (1,190)	
	Repayment of principal portion of lease liability Interest paid on lease hability		(1.190) (1.057)	
	Interest paid on lease inability Interest and other borrowing cost paid	(1.573) (2.107)	(1.057) (746)	
	Net cash generated from / (used in) financing activities (C)	(258)	2,547	
	Net decrease in cash and cash equivalents (A+B+C)	(3,384)	(2,548)	
	Cash and cash equivalents at the beginning of the period	12,118	7,031	
	Cash and cash equivalents at the end of the period	8,734	4,483	
		For the six month	For the six month	
	Break up of cash and cash equivalents at the end of the period	ended	ended	
		30 September 2024	30 September 2023	
	Cash and cash equivalents at the end of the period (before adjustment of bank overdraft)	22,323	4.483	
	Less: Bank overdrafts repayable on demand	(13,589)	-	
	ash and cash equivalents at the end of the period	8,734	4,483	



	HealthCare Global Enterprises Limited
	CIN: L15200KA1998PLC023489
1	Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Kamataka, India
1	Corp. Office: Tower Block, Unity Building Complex, No. 3. Mission Road, Bengaluru 560 027, Karnataka, India
	STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED AND SIX MONTHS ENDED 30 SEPTEMBER 2024
Notes	
1	The statement of standalone financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company') for the quarter and six months ended 30 September 2024 has been reviewed by the Audit Committee and approved by the
	Board of Directors at their respective meetings held on 09 Nov 2024. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the
1	Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclousre requirements) Regulations, 2015.
1	
1	The Statement has been which to limited evolve to the statement of the Common. The evolve event of the auditors is unsuelified

The Statement has been subjected to limited review by the statutory auditors of the Company. The review report of the auditors is unqua

2 Exceptional items:

Bengaluru, 09 November 2024

a) In the earlier years, the Company had recognised impairment aggregating to Rs. 8,355 lakhs (including capital work-in progress, capital advances, right of use asset, security deposit and other committed costs) towards a greenfield project at leased premises in Gurugrain. During the previous year ended 31 March 2024, the underlying lease agreement was terminated and the project was written-off. Further, the management concluded that the other committed project cost of Rs. 300 lakhs which was accrued earlier was no longer payable and was written back in the statement of profit and loss as exceptional items.

b) The Company performed impairment assessment for all its investments. During the previous year ended 31 March 2024, the recoverable amount of investments in HCG Manavata Oncology LLP was estimated to be lower (considering the future cash flows) than its carrying value given the decline in performance and reduced growth rates during the forecast period, resulting into an impairment of Rs. 2,000 lakhs. The Company has total investment of Rs 5,715 lakhs and the total provision for impairment against the aforementioned investment of Rs 2,000 Lakhs as at 31 March 2024.

3 During the previous year ended 31 March 2024, the Company acquired non-controlling partnership interest aggregating to 49.5% in HCG Kolkata Cancer Care LLP (Formerly known as HCG EKO Oncology LLP) as per the terms of Transfer of Partnership Interest Agreement dated 8 March 2024 for a consideration of Rs. 2,000 lakhs. With this acquisition, HCG Kolkata Cancer Care LLP (Formerly known as HCG EKO Oncology LLP) became wholly owned subsidiary of the Company

4 During the previous year ended 31 March 2024, pursuant to the Business Transfer Agreements ("BTA") with SRJ Health Care Private Limited and Amrish Oncology Services Private Limited. the Company acquired their comprehensive cancer care centre and Radiation unit / centre respectively in Indore on a slump sale basis on 3 October 2023. As per the terms of the BTA, the Company paid upfront consideration aggregating to Rs. 4,500 lakhs. The BTA also provides for contingent consideration to be paid after 12 months from the date of acquisition amounting to a maximum of Rs. 1,600 lakhs. The amount of contingent consideration was dependent upon the achievement of financial performance of the business acquired. Based on the Purchase Price Allocation report, an amount of Rs. 4,169 lakhs and Rs. 263 lakhs were recorded as Goodvull and contingent consideration, respectively. The Company incurred Rs. 117 lakhs towards legal and professional fees in respect of this business acquisition which was charged-off in the statement of prit and loss as Other expenses for the previous year ended 31 March 2024.

During the previous quarter ended 30 June 2024, the Management remeasured the fair value of contingent consideration payable as Nil. Consequently, the contingent consideration of Rs 278 lakhs (including interest accounted) was written back in Other measured the quarter ended 30 June 2024.

- 5 During the previous year ended 31 March 2024, pursuant to the Share Purchase Agreement with Nagpur Cancer Hospital & Research Institute Private Limited ("NCHRI") and its sharcholders, the Company acquired 100% equity shares of NCHRI on 22 August 2023 for a consideration of Rs. 1.410 Lakhs. Hence, NCHRI became wholly owned subsidiary of the Company, Further, the Company also acquired remaining non-controlling interest in its subsidiary HCG NCHRI Oncology LLP ("HCG NCHRI") on 22 August 2023 pursuant to the Partnership Transfer Agreement ("PTA") with Dr. Ajay Mehta and Dr. Suchtra Mehta dated 18 July 2023 for a consideration of Rs. 1.700 lakhs. Of the total consideration, Rs 1.340 Lakhs tas been paid and the balance amount of Rs. 420 lakhs will be paid in accordance with the terms of the PTA.
- 6 During the quarter and six months ended 30 September 2024. NIL equity share options (year ended 31 March 2024; 760,000 equity share options at an excercise price of Rs. 200 per share) having a face value of Rs. 10 each have been granted to the eligible employees under the Employee Stock Option Scheme (ESOP Scheme). Further, during the quarter and six months ended 30 September 2024; 38,791 equity shares and 97,046 equity shares respectively (year ended 31 March 2024; 173,625 equity shares) are allotted pursuant to exercise of equity share options.
- 7 The Company entered into a share purchase agreement and shareholder agreement dated 28 June 2024 for the acquisition of shares of Vizag. Hospital And Cancer Research Centre Private Limited (VHCRPL). As per the terms of the agreement, the consideration for the upfront acquisition of 51% equity share capital of VHCRPL is Rs. 20,757 lakhs (approx); consideration for second tranche of 34% of equity share capital of VHCRPL is Rs. 15,500 lakhts (approx) and the consideration for the balance 15% of equity share capital of VHCRPL is Rs. 15,500 lakhts (approx) and the consideration for the balance 15% of equity share capital of VHCRPL is Rs. 15,500 lakhts (approx) and the consideration for the balance 15% of equity share capital of VHCRPL is Rs. 15,500 lakhts (approx) and the consideration for the balance 15% of equity share capital of VHCRPL is Rs. 15,500 lakhts (approx) and the consideration for the balance 15% of equity share capital of VHCRPL is Rs. 15,500 lakhts (approx) and the consideration for the balance 15% of equity share capital of VHCRPL is Rs. 15,500 lakhts (approx) and the consideration for the balance 15% of equity share capital of VHCRPL is Rs. 15,500 lakhts (approx) and the consideration for the balance 15% of equity share capital of VHCRPL is Rs. 15,500 lakhts (approx) and the consideration for the acquisition of first tranche of 51% equity share capital of VHCRPL from 02 Detober 2024, the Company made the payment of Rs. 20,632 lakhts (true up on account of final valuation) for the acquisition of first tranche of 51% equity share capital of VHCRPL from 02 October 2024. The acquisition of the business has not been given effect to during the current quarter ended 30 September 2024.
- 8 The Board of Directors, in their meeting held on 9 November 2024, have approved the following proposed arrangements between the Company and HCG NCHRI Oneology LLP (a wholly owned subsidiary of the Company), effective 1 December 2024

1. Transfer of the diagnostic business by the brand name of Triesta and the PET-CT & Cyclotron business located at Chennai from the Company to HCG NCHRI Oncology LLP by way of a slump sale; and 2 Transfer of the oncology hospital business at Nagpur from HCG NCHRI Oncology LLP to the Company by way of a slump sale. The slump sale agreements, once entered, would be accounted for as per the guidance contained in Indian Accounting Standards (IND AS) 103. Business Combination, in the standalone financial statements of the respective entity

9 The Company has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.

For and on behalt of the Board Directors 6 Dr. B. S. Aiaiku **Executive** Chairma





Chartered Accountants

Embassy Golf Links Business Park Pebble Beach, B Block, 3rd Floor No. 13/2, off Intermediate Ring Road Bengaluru - 560 071, India Telephone: +91 80 4682 3000 Fax: +91 80 4682 3999

Limited Review Report on unaudited consolidated financial results of HealthCare Global Enterprises Limited for the quarter ended 30 September 2024 and year to date results for the period from 1 April 2024 to 30 September 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of HealthCare Global Enterprises Limited

- 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of HealthCare Global Enterprises Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net loss after tax and total comprehensive loss of its joint venture for the quarter ended 30 September 2024 and year to date results for the period from 1 April 2024 to 30 September 2024 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
- 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

- 4. The Statement includes the results of the entities mentioned in Annexure I of this limited review report:
- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed, or that it contains any material misstatement.

B 5 R & Co. (a partnership firm with Registration No. BA61223) converted into B 5 R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013 Registered Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Page 1 of 4

B S R & Co. LLP

Limited Review Report (Continued)

HealthCare Global Enterprises Limited

6. We did not review the interim financial information of 10 subsidiaries and 5 step down subsidiaries included in the Statement, whose interim financial information reflect total assets (before consolidation adjustments) of Rs. 50,233 lakhs as at 30 September 2024 and total revenues (before consolidation adjustments) of Rs. 9,884 lakhs and Rs.19,099 lakhs, total net profit after tax (before consolidation adjustments) of Rs. 290 lakhs and Rs. 390 lakhs and total comprehensive income (before consolidation adjustments) of Rs.326 lakhs and Rs. 490 lakhs, for the quarter ended 30 September 2024 and for the period from 1 April 2024 to 30 September 2024 respectively, and cash inflows (net) (before consolidation adjustments) of Rs. 37 lakhs for the period from 1 April 2024 to 30 September 2024. as considered in the Statement. The Statement also include the Group's share of net loss after tax of Rs. 3 lakhs and Rs. 4 lakhs and total comprehensive loss of Rs. 3 lakhs and Rs. 4 lakhs, for the guarter ended 30 September 2024 and for the period from 1 April 2024 to 30 September 2024 respectively as considered in the Statement, in respect of a joint venture, whose interim financial information has not been reviewed by us. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint venture, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

For B S R & Co. LLP Chartered Accountants Firm's Registration No.:101248W/W-100022

Vikash Gupta Partner Membership No.: 064597 UDIN:24064597BKDHRM4954

Bangalore 09 November 2024

BSR&Co.LLP

Limited Review Report (Continued) HealthCare Global Enterprises Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship	Country of incorporation
1	BACC Healthcare Private Limited	Subsidiary	India
2	HCGMedi-Surge Hospitals Private Limited	Subsidiary	India
3	HCG Oncology LLP	Subsidiary	India
4	HCG Oncology Hospitals LLP (formerly known as Apex HCG Oncology Hospitals LLP)	Subsidiary	India
5	HCG Manavata Oncology LLP	Subsidiary	India
6	Malnad Hospital & Institute of Oncology Private Limited	Subsidiary	India
7	HealthCare Diwan Chand Imaging LLP	Subsidiary	India
8	HCG NCHRI Oncology LLP	Subsidiary	India
9	Nagpur Cancer Hospital & Research Institute Private Limited*	Subsidiary	India
10	HCG Kolkata Cancer Care LLP (formerly known as HCG EKO Oncology LLP)	Subsidiary	India
11	HCG Rajkot Hospitals LLP (formerly known as HCG Sun Hospitals LLP)	Subsidiary	India
12	Niruja Product Development & Healthcare Research Private Limited	Subsidiary	India
13	HealthCare Global Senthil Multi Specialty Private Limited	Subsidiary	India
14	Suchirayu Health Care Solutions Limited	Subsidiary	India
15	HCG (Mauritius) Pvt. Ltd.	Subsidiary	Mauritius
16	HealthCare Global (Africa) Private Limited	Step-down subsidiary	Mauritius

Page 3 of 4

BSR&Co.LLP

Limited Review Report (Continued)

HealthCare Global Enterprises Limited

Sr. No	Name of component	Relationship	Country of incorporation
17	Healthcare Global (Uganda) Private Limited	Step-down subsidiary	Uganda
18	Healthcare Global (Tanzania) Private Limited	Step-down subsidiary	Tanzania
19	Healthcare Global (Kenya) Private Limited	Step-down subsidiary	Kenya
20	Cancer Care Kenya Limited	Step-down subsidiary	Kenya
21	Advanced Molecular Imaging Limited	Joint Venture	Kenya
*Acquir	red with effect from 22 August 2023.		



	C Regd. Office: HCG Tower, No. 8. P Kalim		023489 1ma Nagar, Bengaluru 56				
	Corp. Office: Tower Block. Unity Build STATEMENT OF UNAUDITED CONSOLIDATED FINANC				0 SEPTEMBER 2024		
						(Rs. in Lakhs	except share data)
SI. No.	Particulars	Quarter ended 30 September 2024	Preceding quarter ended 30 June 2024	Corresponding quarter ended 30 September 2023	Six months ended 30 September 2024	Six months ended 30 September 2023	Previous year ended 31 March 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Income (a) Revenue from operations	55.247	52,469	48.596	107,716	94,507	190.787
	(b) Income from government grant	107	89	98	196	195	425
	(c) Other income (refer note 4)	1,113	881	340	1,994	582	1.694
	Total income	56,467	53,439	49,034	109,906	95,344	192,906
2							
	Expenses	14,864	13.574	12,209	28,438	24,213	47,937
	(a) Purchases of medical and non-medical items (b) Changes in an arterized	(441)	(251)	(123)	(692)	(336)	(395)
	(b) Changes in inventories	8,527	8,516	7.716	17,043	(550)	30,824
	(c) Employee benefits expense (d) Finance costs	3,598	3,371	2,689	6,969	5,244	10.874
		4,974	4,701	4,321	9,675	8,422	17,436
	(e) Depreciation and amortisation expense (f) Medical consultancy charges	11.789	11,205	10,628	22,994	20,366	41,357
		10.388	10,423	9,801	20.811	19,219	38,530
	(g) Other expenses (refer notes 4 and 5) Total expenses	53,699	51,539	47,241	105,238	92,534	186,563
			1.000	1			() ()
	Profit before share of profit / (loss) of joint venture, exceptional items and tax (1-2)	2,768	1,900	1,793	4,668	2,810	6,343 30
	Share of profit (loss) of joint venture	(3)	(1)	(1)	(4)	34	6,382
	Profit before exceptional items and tax (3+4)	2,765	1,899	1,792	4,664	2,844	6,382 390
	Exceptional item (refer note 2)		-	-	-	2,844	6,772
	Profit before tax (5+6)	2,765	1,899	1,792	4,664	2,8++	6,772
8	Tax expense	1.105	767	852	1.872	1,803	3,432
	- Current tax	(408)	(231)	(138)	(639)	(402)	(792)
	- Deferred tax						
	Total tax expense	697	536	714	1,233	1,401	2,640
	Profit for the period / year (7-8)	2,068	1,363	1,078	3,431	1,443	4,132
	Other comprehensive income / (loss) (i) Items that will not be reclassified subsequently to profit or loss						
- 1	- Remeasurements of the defined benefit plans	-	-	-	-		(80)
	- Income tax effect on above	-	-	-	-	-	15
	(ii) Items that will be reclassified to profit or loss						
	- Exchange differences on translation of financial statements of foreign operations	36	64	(137)	100	(289)	18
	Other comprehensive income / (loss) for the period / year, net of tax	36	64	(137)	100	(289)	(47)
11	Total comprehensive income for the period / year (9+10)	2,104	1,427	941	3,531	1,154	4,085
	Profit / (loss) for the period /year attributable to:						
	Owners of the Company	1.799	1,208	1.357	3,007	2,118	4.814
	Non-controlling interests	269	155	(279)	424	(675)	(682)
	Other comprehensive income / (loss) for the period / year attributable to						
	Owners of the Company	39	43	(132)	82	(272)	(43)
	Non-controlling interests	(3)	21	(5)	18	(17)	(4)
	Total comprehensive income / (loss) for the period / year attributable to	1	-			1	
	Owners of the Company	1.838	1.251	1.225	3,089	1.846	4,771
	Non-controlling interests	266	176	(284)	442	(692)	(686)
	Paid-up equity share capital (Face value of Rs 10 each)	13,939	13.935	13.926	13,939	13,926	13.929
	Reserves, i.e., 'Other equity'						68,649
14	Earnings per equity share (face value of Rs. 10 each)	Not annualised	Not annualised	Not annualised	Not annualised	Not annualised	Annualised
	(a) Basic (Rs.)	1 29	0.87	0.97	2.16	1 52	3 40 3.43
	(b) Diluted (Rs)	1 28	0.86	0.97	2.14	1 51	3.43
	See accompanying notes to the Consolidated Financial Results						



	CONSOLIDATED BALANCE SHEET		(Rs in Lakhs
	Particulars	As at 30 Sep 2024 Unaudited	As at <u>31 March 2024</u> Audited
	ASSETS		
	Non-current assets		
	(a) Property, plant and equipment	115,200	101,469
	(b) Capital work in progress	3,565	8,318
	(c) Right-of-use assets	68,725 22,302	22,294
	(d) Goodwill	2,887	2.987
	(e) Other intangible assets (f) Investment in equity accounted investee	401	336
	(g) Financial assets		
ľ	(i) Investments	700	697
	(ii) Other financial assets	5,698	4,862
	(h) Deferred tax assets (net)	795	706
	(i) Other tax assets (net)	6,998	7,697
	Other non-current assets	4,144	4,333
ľ	Fotal non-current assets	231,415	202,765
1	Current assets		
	a) Inventories	4,959	4.267
0	b) Financial assets		
	(i) Trade receivables	35,602	29,403
	(ii) Cash and eash equivalents	27,821	27.261 3.046
	 (iii) Bank balance other than eash and eash equivalents above (ix) Loans 	242	5.040
	(iv) Loans (v) Other financial assets	591	678
	c) Other unrent assets	4,884	3.136
	Fotal current assets	75,293	67,985
- 1	Fotal assets	306,708	270,750
	EQUITY AND LIABILITIES		
- II	Equity		
(a) Equity share capital	13,939	13,929
(b) Other equity	72,240	08.049
	Equity attributable to equity holders of the Company	86,179	82,578
	vion- controlling interests	4.376	3.934
[1	Fotal equity	90.555	86,512
	Liabilities		
	Non-current liabilities		
	a) Financials Liabilities		
	(i) Borrowings	51,042	48,530
	(ii) Lease liabilities	76,157	55,882
(b) Provisions	1.578	1.566
- (Deferred tax liabilities (net) 	58	608
I '	d) Other non-current liabilities	3,775	3.282
1	Fotal non-current liabilities	132,610	109,868
	Current liabilities		
	a) Financials liabilities		
ľ	(1) Borrowings	23,947	18,746
	(ii) Lease liabilities	4.649	4.279
	(iii) Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	659	621
	Total outstanding dues of creditors other than micro enterprises and small enterprises	31,868	27,485
	(iv) Other financial liabilities	16,191	16,365
Ľ	b) Other current liabilities	4,019	4,826
I *	c) Provisions	1.910	1,828
	d) Current tax liabilities (net)	300	220
	Total current liabilities	83,543	74,370
11	Fotal equity and liabilities	306,708	270,750

HealthCare Global Enterprises Limited CIN: L15200KA1998PLC023489

Kamataka. India amataka. India NTHS ENDED 30 SEPTEMBER 2024



HealthCare Global Enterprises Limited CIN : L15200KA1998PLC023489 Regd. Office: HCG Tower. No. 8, P Kalinga Rao Road, Sampangi Rama Nagar. Bengaluru 560 027, Karnataka, India Corp. Office: Tower Block. Unity Building Complex, No. 3. Mission Road, Bengaluru 560 027, Karnataka, India STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2024

Consolidated Cash Flow Statement		(Rs in Lakhs)
	For the six month	For the six month
Particulars	ended 30 September 2024	ended 30 September 2023
	Unaudited	Unaudited
Cash flows from operating activities	Chaudheu	Chandlied
Profit before tax	4,664	2,844
Adjustments for:	1,001	2.011
Finance costs	6,969	5.244
Gain on investment revalued at FVTPL	(4)	(6)
Loss on disposal of property, plant and equipment	(15)	36
Loss allowance on trade receivables	1,339	1,387
Expenses on employee stock option scheme	385	397
Interest income	(912)	(493)
Net gain on termination of lease	(63)	(2)
Remeasurement of contingent consideration (refer note 4)	(278)	-
Payables no longer required written-back	-	(7)
Depreciation and amortisation expense	9,675	8,422
Income from government grant	(196)	(195)
Net foreign exchange (gain)	(40)	(31)
Share of (profit) 'loss of equity accounted investee	3	(34)
Movements in working capital:		
Changes in trade receivables	(7,500)	(5,810)
Changes in inventories	(692)	(336)
Changes in loans, financial assets and other assets	(3,798)	(3.815)
Changes in trade payables, financial liabilities and other liabilities	3,919	2.307
Changes in provisions	93	336
Cash generated from operations	13,549	10,244
Income taxes paid (net of refunds)	(961)	(3,875)
Net cash generated from operating activities (A)	12,588	6,369
Cash flows from investing activities		
Fixed deposits invested	(373)	(1,703)
Proceeds from maturity of fixed deposits	1.988	1,636
Acquisition of property, plant and equipment and others	(13.244)	(6,369)
Proceeds from disposal of property, plant and equipment	85	9
Interest received	691	444
Invesment in a joint venture	(68)	-
Payment for asset acquisition (net of eash and eash equivalents)	-	(353)
Net cash (used) in investing activities (B)	(10,921)	(6,336)
Cash flows from financing activities		
Proceeds from issue of equity shares	125	151
Acquisition of non-controlling interest	-	(2.220)
Proceeds from long-term borrowings	8.417	16.002
Repayment of long-term borrowings	(4.243)	(12,623)
Repayment of principle portion of lease liability	(1.759)	(2.226)
Interest paid on lease liability	(3,357)	(2,395)
Settlement of deferred consideration	(210)	-
Interest and other borrowing cost paid	(3,465)	(2.426)
Net cash (used) in financing activities (C)	(4,492)	(5,737)
Net decrease in cash and cash equivalents (A+B+C)	(2,825)	(5,704)
Cash and eash equivalents at the beginning of the period	16,602	17,118
Cash and cash equivalents at the end of the period	13,777	11,414

Break up of cash and cash equivalents at the end of the period	For the six month ended 30 September 2024	For the six month ended 30 September 2023
Cash and cash equivalents at the end of the period (before adjustment of bank overdraft)	27,821	11,807
Less Bank overdrafts repayable on demand	(14.044)	(393)
Cash and cash equivalents at the end of the year period	13,777	11,414

Global En e hCal Bangalore Ses

	HealthCare Global Enterprises Limited
	CIN: L15200KA1998PLC023489
1	Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
	Corp. Office: Tower Block. Unity Building Complex. No. 3, Mission Road. Bengaluru 560 027, Karnataka, India STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2024
Notes	: The statement of unaudited consolidated financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company'), its subsidiaries (collectively referred to as 'the Group') and its joint venture, for the quarter and six months ender 30 September 2024 has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 09 November 2024. The Statement has been prepared in accordance with Indian Accounting Standards (Inc AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act., 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.
	The Statement has been subjected to limited review by the statutory auditors of the Company. The review report of the auditors is unqualified.
2	Exceptional items:
	In the earlier years, the Company had recognised impairment aggregating to Rs. 8,355 lakhs (including capital work-in progress, capital advances, right of use asset, security deposit and other committed costs) towards a greenfield project at lease premises in Gurugram. During the previous year ended 31 March 2024, the underlying lease agreement was terminated and the project was written-off. Further, the management concluded that the other committed project cost of Rs. 390 lakh which was accrued earlier was no longer payable and was written back in the statement of profit and loss as exceptional items
3	During the previous year ended 31 March 2024, the Company acquired non-controlling partnership interest aggregating to 49.5% in HCG Kolkata Cancer Care LLP (Formerly known as HCG EKO Oncology LLP) as per the terms of Transfer of Partnership Interest Agreement dated 8 March 2024 for a consideration of Rs. 2,000 lakhs. With this acquisition, HCG Kolkata Cancer Care LLP (Formerly known as HCG EKO Oncology LLP) became wholly owned subsidiary of the Company.
4	During the previous year ended 31 March 2024, pursuant to the Business Transfer Agreements ("BTA") with SRJ Health Care Private Limited and Amrish Oneology Services Private Limited, the Company acquired their comprehensive cancer care centre and Radiation unit / centre respectively in Indore on a slump sale basis on 3 October 2023 As per the terms of the BTA, the Company paid upfront consideration aggregating to Rs 4.500 lakhs. The BTA also provides for contingen consideration to be paid after 12 months from the date of acquisition amounting to a maximum of Rs 1.600 lakhs. The amount of contingent consideration was dependent upon the achievement of financial performance of the business acquired Based on the Purchase Private Allocation. respectively. The Company incurred Rs. 117 lakhs towards legal and professional fees in respect of this business acquisition which was charged-off in the statement of profit and loss as Other expenses for the previous year ended 31 March 2024.
	During the previous quarter ended 30 June 2024, the Management remeasured the fair value of contingent consideration payable as Nil. Consequently, the contingent consideration of Rs 278 lakhs (including interest accounted) has been written back in Other income during the previous quarter ended 30 June 2024.
5	During the previous year ended 31 March 2024, the Group disposed-off an IVF facility of its subsidiary. BACC Healtheare Private Limited, at Delhi for a consideration of Rs. 100 lakhs. Consequential loss of Rs. 102 lakhs towards loss on disposa of this IVF facility was charged-off in the statement of profit and loss as Other expenses.
6	During the previous year ended 31 March 2024, pursuant to the Share Purchase Agreement with Nagpur Cancer Hospital & Research Institute Private Limited ("NCHRI") and its shareholders, the Company acquired 100% equity shares of NCHR on 22 August 2023 for a consideration of Rs. 1.410 Lakh. The management concluded this acquisition as an asset acquisition. The Company also acquired remaining non-controlling interest in its subsidiary. HCG NCHRI Oncology, LLP on 2. August 2023 pursuant to the Partnership Transfer Agreement ("PTA") with Dr. Ajay Mehta and Dr. Suchitra Mehta dated 18 July 2023 for a consideration of Rs. 1.760 lakhs. Of the total consideration, Rs. 1.340 Lakhs has been paid and the balanc amount of Rs. 420 lakhs will be paid in accordance with the terms of the PTA.
7	During the quarter and six months ended 30 September 2024. NIL equity share options (year ended 31 March 2024 760.000 equity share options at an excercise price of Rs. 200 per share) having a face value of Rs. 10 each have been granted to the eligible employees under the Employee Stock Option Scheme (ESOP Scheme). Further, during the quarter and six months ended 30 September 2024, 38,791 equity shares and 97,046 equity shares respectively (year ended 31 March 2024, 173,62) equity shares) are allotted pursuant to exercise of equity share options.
×	The Company entered into a share purchase agreement and shareholder agreement dated 28 June 2024 for the acquisition of shares of Vizag. Hospital And Cancer Research Centre Private Limited (VHCRPL). As per the terms of the agreement, the consideration for the upfront acquisition of 51% equity share capital of VHCRPL is Rs 20,757 lakhs (approx); consideration for second tranche of 34% of equity share capital of VHCRPL is Rs 15,500 lakhs (approx); and the consideration for the balance 15% of equity share capital will be determined as per the terms of the shareholder agreement. This was approved by the Board of Directors of the Company, in their meeting held on 02 July 2024. On 01 October 2024, the Company made the payment of Rs 20,652 lakhs (true up on account of final valuation) for the acquisition of first tranche of 51% equity share capital of VHCRPL from 02 October 2024. The acquisition of the business has not beer given effect to during the current quarter ended 30 September 2024.
9	The Board of Directors, in their meeting held on 9 November 2024, have approved the following proposed arrangements between the Company and HCG NCHRI Oncology LLP (a wholly owned subsidiary of the Company), effective 1 December 2024:
	1. Transfer of the diagnostic business by the brand name of Triesta and the PET-CT & Cyclotron business located at Chennai from the Company to HCG NCHRI Oncology LLP by way of a slump sale; and 2. Transfer of the oncology hospital business at Nagpur from HCG NCHRI Oncology LLP to the Company by way of a slump sale. The slump sale agreements, once entered, would be accounted for as per the guidance contained in Indian Accounting Standards (IND AS) 103: Business Combination, in the standalone financial statements of the respective entity.
10	The Group has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'
	For and on behal of the Board of Directors
	For and on behalf of the Board of Directors
[1/2×11 ml
	(pr. 6. S. Australian)
	Bengaluru, 09 November 2024 Executive Chairman
	,
	Bangalore B
	FRONT * CT